Prior to joining Thrive, she was vice president, head of public policy for Foundation Medicine, where she was responsible for developing, advocating and executing company positions before Congress and the U.S. Food and Drug Administration (FDA), including the landmark parallel review decision by the FDA and Centers for Medicare and Medicaid Services (CMS) on next generation sequencing for Foundation Medicine’s flagship product. Before that, she spent time outside of the industry, as senior counsel to Senator Arlen Specter, where she was lead policy and strategic advisor for issues related to tax, banking, healthcare and finance. Prior to that, she was lead counsel to the Senate Judiciary Committee, providing policy analysis and strategic counsel to both Chairman Specter and Republican and Democrat senators on the Committee.
The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.